Amgen Inc is a drug manufacturers - general business with stocks listed in the US. Amgen shares (AMGN) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was US$273.01 – an increase of 3.9% over the previous week. Here's how to invest if you're based in Australia.
Our top pick for
US stocks
Our top pick for
Best for beginner
Our top pick for
Dividend investing
Amgen's shares were split on a 2:1 basis on 21 November 1999. So if you had owned 1 share the day before the split, the next day you would own 2 shares. This wouldn't directly have changed the overall worth of your Amgen shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Amgen shares which in turn could have impacted Amgen's share price.
| 52-week range | US$206.7538 - US$327.1625 |
|---|---|
| 50-day moving average | US$280.0228 |
| 200-day moving average | US$271.0247 |
| Target price | US$307.5 |
| PE ratio | 21.2682 |
| Dividend yield | US$8.52 (3.39%) |
| Earnings per share (TTM) | US$12.49 |
Use the fields above to explore the returns from a historical investment. Please refer to the charts further up this page to see performance over 5 years, or other periods. Past performance doesn't indicate future results. Capital is at risk.
Historical closes compared with the last close of $273.01
| 1 week (2024-04-18) | 3.90% |
|---|---|
| 1 month (2024-03-25) | -2.78% |
| 3 months (2024-01-25) | -12.01% |
| 6 months (2023-10-25) | 0.31% |
| 1 year (2023-04-24) | 11.68% |
|---|---|
| 2 years (2022-04-22) | 9.05% |
| 3 years (2021-04-23) | 6.22% |
| 5 years (2019-04-25) | 51.27% |
The technical analysis gauge below displays real-time ratings for the timeframes you select. However, this is not a recommendation. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Valuing Amgen stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Amgen's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Amgen's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 21x. In other words, Amgen shares trade at around 21x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Amgen's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 2.3869. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Amgen's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Amgen's EBITDA (earnings before interest, taxes, depreciation and amortisation) is US$12.2 billion (£9.8 billion).
The EBITDA is a measure of a Amgen's overall financial performance and is widely used to measure stock profitability.
Over the last 12 months, Amgen's shares have ranged in value from as little as US$206.7538 up to US$327.1625. A popular way to gauge a stock's volatility is its "beta".
Beta measures a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Amgen's is 0.595. This would suggest that Amgen's shares are less volatile than average (for this exchange).
| Revenue TTM | US$28.2 billion |
|---|---|
| Operating margin TTM | 8.15% |
| Gross profit TTM | US$19.9 billion |
| Return on assets TTM | 6.29% |
| Return on equity TTM | 135.79% |
| Profit margin | 23.83% |
| Book value | 11.64 |
| Market capitalisation | US$142.4 billion |
TTM: trailing 12 months
Dividend payout ratio: 46.97% of net profits
Recently Amgen has paid out, on average, around 46.97% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 3.39% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Amgen shareholders could enjoy a 3.39% return on their shares, in the form of dividend payments. In Amgen's case, that would currently equate to about $8.52 per share.
While Amgen's payout ratio might seem fairly standard, it's worth remembering that Amgen may be investing much of the rest of its net profits in future growth.
Amgen's most recent dividend payout was on 6 June 2024. The latest dividend was paid out to all shareholders who bought their shares by 15 May 2024 (the "ex-dividend date").
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Amgen.
When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.
Total ESG risk: 20.95
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Amgen's overall score of 20.95 (as at 12/31/2018) is pretty good – landing it in it in the 24th percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like Amgen is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
Environmental score: 1.53/100
Amgen's environmental score of 1.53 puts it squarely in the 3rd percentile of companies rated in the same sector. This could suggest that Amgen is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
Social score: 15.13/100
Amgen's social score of 15.13 puts it squarely in the 3rd percentile of companies rated in the same sector. This could suggest that Amgen is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
Governance score: 5.8/100
Amgen's governance score puts it squarely in the 3rd percentile of companies rated in the same sector. That could suggest that Amgen is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
Controversy score: 2/5
ESG scores also evaluate any incidences of controversy that a company has been involved in. Amgen scored a 2 out of 5 for controversy – the second-highest score possible, reflecting that Amgen has, for the most part, managed to keep its nose clean.
Amgen Inc was last rated for ESG on: 2019-01-01.
| Total ESG score | 20.95 |
|---|---|
| Total ESG percentile | 23.7 |
| Environmental score | 1.53 |
| Environmental score percentile | 3 |
| Social score | 15.13 |
| Social score percentile | 3 |
| Governance score | 5.8 |
| Governance score percentile | 3 |
| Level of controversy | 2 |
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.
Everything we know about the Sun Silver IPO, plus information on how to buy in.
Everything we know about the Tasmea Limited IPO, plus information on how to buy in.
Steps to owning and managing Far Northern Resources shares.
Commodity ETFs can be used to hedge against inflation. Here's what they do, why they should be on your watchlist and how they can help your portfolio.
Looking for the best performing stocks in Australia? We update this list weekly.
Steps to owning and managing Gol Linhas Aéreas Inteligentes SA shares from Australia.
Trade ASX stocks and ETFs with a $2 brokerage fee and a low minimum investment of just $10.
These ETFs have the lowest fees on the market, but does that make them the best?
You've heard of CommSec but how does it stack up to the likes of IG, CMC Invest and other players in the market?
Westpac Share Trading allows you to take control of your investments. Find out if its right for you.
